2018 Press Releases

Keyword Search
 
DateTitle 
02/21/18AbbVie Announces Positive Topline Results from Phase 3 Study Evaluating Investigational Elagolix in Women with Uterine Fibroids
- First of two pivotal Phase 3 studies met primary efficacy endpoint and all ranked secondary endpoints - Results demonstrated elagolix, in combination with low-dose add-back therapy, reduced heavy menstrual bleeding compared to placebo - Data will be presented at an upcoming medical conference NORTH CHICAGO, Ill., Feb. 21, 2018 /PRNewswire/ -- AbbVie (NYSE:ABBV), a global research and development-based biopharmaceutical company, in cooperation with Neurocrine... 
Printer Friendly Version
02/14/18Neurocrine Biosciences Will File New Drug Application for Opicapone for Parkinson's Disease Based on Existing Pivotal Clinical Trial Data
Neurocrine Plans to File the NDA During the First Half of 2019 SAN DIEGO, Feb. 14, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that the U.S. Food and Drug Administration (FDA) has provided guidance on the regulatory path forward to support the New Drug Application (NDA) for opicapone, an investigational drug for Parkinson's disease, after receiving meeting minutes from the Ja... 
Printer Friendly Version
02/13/18Neurocrine Biosciences Reports Fourth Quarter and Year-End 2017 Financial Results and Provides Investor Update for 2018
INGREZZA® (valbenazine) Fourth Quarter Net Product Sales of $64.5 Million with Approximately 9,100 TRx INGREZZA Net Product Sales of $116.6 Million with Approximately 14,900 TRx Since Commercial Launch on May 1, 2017 Total Revenue for the Fourth Quarter of 2017 was $94.5 Million and $161.6 Million for the Full-Year 2017 Elagolix PDUFA Action Date for Endometriosis in Q2 2018 and Uterine Fibroids Data from Two Phase III Studies Expected in Q1 2018 Results from Phase IIb Study of Valbe... 
Printer Friendly Version
02/08/18Neurocrine Biosciences to Present at the Leerink Partners 7th Annual Global Healthcare Conference
Live Audio Webcast Will be on February 15, 2018 SAN DIEGO, Feb. 8, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Leerink Partners 7th Annual Global Healthcare Conference at 11:30 a.m. ET on Thursday, Feb. 15, 2018, in New York City. Kevin Gorman, CEO of Neurocrine Biosciences, will present at the conference. The live presentation will be webcast and may be accessed on the Company's website under Investors at http://www.neurocrine.com. A replay of the ... 
Printer Friendly Version
02/06/18Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2017 Financial Results
Conference Call and Webcast Scheduled for Tuesday, February 13 SAN DIEGO, Feb. 6, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report fourth quarter and year-end 2017 financial results after the Nasdaq market closes on Tuesday, Feb. 13, 2018. Neurocrine will then host a conference call and webcast to discuss its financial results and provide a Company update that day at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time). Participants can acces... 
Printer Friendly Version
01/07/18Neurocrine Biosciences Announces Retirement of Christopher O'Brien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief Medical Officer
SAN DIEGO, Jan. 7, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, today announced that Christopher O'Brien, M.D., Chief Medical Officer, has notified the Company he plans to retire in February 2018, after a transition period with his successor. Dr. O'Brien joined Neurocrine in 2005, and has led the clinical development and medical affairs activities for more than 12 years. Dr. O'Brien will remain ... 
Printer Friendly Version
01/07/18Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones
- Total Preliminary Revenue for the Fourth Quarter of 2017 was Approximately $94 Million and $161 Million for the Full-Year 2017 - INGREZZA® (valbenazine) Preliminary Fourth Quarter Net Product Sales of Approximately $64 Million with Approximately 9,100 TRx - Received $30 Million Milestone from AbbVie for the Elagolix Endometriosis NDA Acceptance During the Fourth Quarter of 2017 - INGREZZA® (valbenazine) Preliminary Net Product Sales of Approximately $116 Million with Approximately 14,... 
Printer Friendly Version
01/02/18Neurocrine Biosciences to Present at the 36th Annual J.P. Morgan Healthcare Conference
Live Audio Webcast Will be on January 8, 2018 SAN DIEGO, Jan. 2, 2018 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the 36th Annual J.P. Morgan Healthcare Conference at 3:00 p.m. PT (6:00 p.m. ET) on Monday, Jan. 8, 2018, in San Francisco. Kevin Gorman, CEO of Neurocrine Biosciences, will present at the conference. The live presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com. A replay of the presentation will ... 
Printer Friendly Version